Abbott has finalized the Exact Sciences acquisition, marking the completion of a deal first announced in November 2025 to acquire the Madison, Wisconsin-based cancer diagnostics developer. The company agreed to pay $21 million for Exact Sciences and raised $20 billion through a notes offering earlier this month to support the transaction. With the Exact Sciences acquisition now closed, the company has formally integrated the business into its broader diagnostics portfolio.
The acquisition strengthens Abbott’s position in cancer screening and diagnostics, a segment experiencing rapid growth. Through this deal, Abbott expands its reach to millions more patients by leveraging Exact Sciences’ product portfolio. This includes Cologuard, a non-invasive test designed for colorectal cancer screening, alongside a range of established and emerging diagnostic tools aimed at improving early detection and disease management.
Exact Sciences brings a suite of solutions such as Oncotype Dx, Cancerguard for multi-cancer early detection and Oncodetect, which supports molecular residual disease identification and recurrence monitoring. Abbott highlighted that the company’s pipeline includes next-generation diagnostics focused on detecting cancer at earlier stages, enabling improved treatment decisions and ongoing monitoring. These capabilities are expected to enhance care pathways and support more personalized treatment approaches.
Following the transaction, Exact Sciences will operate as a wholly owned subsidiary of Abbott. The medtech company anticipates the acquisition will contribute approximately $3 billion in incremental sales in 2026. “Abbott’s global scale, track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important tools for early cancer detection and personalized treatments,” said Robert B. Ford, chair and CEO, Abbott. “With the legacy and deep expertise of the Exact Sciences team, we’re ready to transform cancer care.”
